TY - JOUR
T1 - Impact of sixteen established pancreatic cancer susceptibility loci in American Jews
AU - Streicher, Samantha A.
AU - Klein, Alison P.
AU - Olson, Sara H.
AU - Amundadottir, Laufey T.
AU - DeWan, Andrew T.
AU - Zhao, Hongyu
AU - Risch, Harvey A.
N1 - Funding Information:
This work was supported by grants from the National Cancer Institute (F31 CA 177153 to S.A. Streicher; R01 CA098870 to H.A. Risch; P50 CA062924 and R01 CA097075 to A.P. Klein; and P30 CA008748 to S.H. Olson) and by grants from the Geoffrey Beene Foundation, the Arnold and Arlene Goldstein Family Foundation, and the Society of the Memorial Sloan Kettering Cancer Center (to S.H. Olson).
Funding Information:
High-performance computing (HPC) was supported by HPC facilities operated by, and the staffs of, the Yale Center for Research Computing and Yale's W.M. Keck Biotechnology Laboratory, as well as U.S. National Institutes of Health grants RR019895 and RR029676, which helped fund the HPC cluster. The cooperation of 30 Connecticut hospitals, including Stam-ford Hospital, in allowing patient access is gratefully acknowledged.
Funding Information:
1Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut. 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland. 3Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, Maryland. 4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 5Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 6Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut. 7Program of Computational Biology and Bioinformat-ics, Yale University, New Haven, Connecticut. Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).
Publisher Copyright:
©2017 AACR.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Background: The higher risk of pancreatic cancer in Ashkenazi Jews compared with non-Jews is only partially explained by the increased frequency of BRCA1 and BRCA2 mutations in Ashkenazi Jews. Methods: We evaluated the impact of 16 established pancreatic cancer susceptibility loci in a case–control sample of American Jews, largely Ashkenazi, including 406 full-Jewish pancreatic cancer patients and 2,332 full-Jewish controls, genotyped as part of the Pancreatic Cancer Cohort and Case–Control Consortium I/II (PanScan I/II), Pancreatic Cancer Case-Control Consortium (PanC4), and Resource for Genetic Epidemiology Research on Adult Health and Aging (GERA) datasets. We compared risk in full-Jewish subjects with risk in part-Jewish; non-Jewish Southern European; and in the combined non-Jewish Eastern, Northern, Southern, and Western European (non-Jewish white European) subjects from the same datasets. Jewish ancestries were genetically identified using seeded Fast principal component analysis. Data were analyzed by unconditional logistic regression, and adjusted for age, sex, and principal components. Results: One SNP on chromosome 13q22.1 (rs9543325; OR, 1.36; 95% confidence interval, 1.16–1.58; P = 10-4.1) was significant in full-Jews. Individual ORs and minor allele frequencies were similar between Jewish and non-Jewish white European subjects. The average ORs across the 16 pancreatic cancer susceptibility loci for full-Jewish, full- plus part-Jewish, non-Jewish Southern European, and non-Jewish white European subjects were 1.25, 1.30, 1.31, and 1.26, respectively. Conclusions: The 16 pancreatic cancer susceptibility loci similarly impact Jewish and non-Jewish white European subjects, both individually and as summary odds. Impact: These 16 pancreatic cancer susceptibility loci likely do not explain the higher risk seen in Ashkenazi Jews.
AB - Background: The higher risk of pancreatic cancer in Ashkenazi Jews compared with non-Jews is only partially explained by the increased frequency of BRCA1 and BRCA2 mutations in Ashkenazi Jews. Methods: We evaluated the impact of 16 established pancreatic cancer susceptibility loci in a case–control sample of American Jews, largely Ashkenazi, including 406 full-Jewish pancreatic cancer patients and 2,332 full-Jewish controls, genotyped as part of the Pancreatic Cancer Cohort and Case–Control Consortium I/II (PanScan I/II), Pancreatic Cancer Case-Control Consortium (PanC4), and Resource for Genetic Epidemiology Research on Adult Health and Aging (GERA) datasets. We compared risk in full-Jewish subjects with risk in part-Jewish; non-Jewish Southern European; and in the combined non-Jewish Eastern, Northern, Southern, and Western European (non-Jewish white European) subjects from the same datasets. Jewish ancestries were genetically identified using seeded Fast principal component analysis. Data were analyzed by unconditional logistic regression, and adjusted for age, sex, and principal components. Results: One SNP on chromosome 13q22.1 (rs9543325; OR, 1.36; 95% confidence interval, 1.16–1.58; P = 10-4.1) was significant in full-Jews. Individual ORs and minor allele frequencies were similar between Jewish and non-Jewish white European subjects. The average ORs across the 16 pancreatic cancer susceptibility loci for full-Jewish, full- plus part-Jewish, non-Jewish Southern European, and non-Jewish white European subjects were 1.25, 1.30, 1.31, and 1.26, respectively. Conclusions: The 16 pancreatic cancer susceptibility loci similarly impact Jewish and non-Jewish white European subjects, both individually and as summary odds. Impact: These 16 pancreatic cancer susceptibility loci likely do not explain the higher risk seen in Ashkenazi Jews.
UR - http://www.scopus.com/inward/record.url?scp=85031676494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031676494&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-17-0262
DO - 10.1158/1055-9965.EPI-17-0262
M3 - Article
C2 - 28754795
AN - SCOPUS:85031676494
SN - 1055-9965
VL - 26
SP - 1540
EP - 1548
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 10
ER -